Results 61 to 70 of about 14,494 (232)

Clinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in HIV-infected patients: efficacy, safety and tolerance [PDF]

, 2017
[Abstract] Two integrase inhibitors (INSTIs), dolutegravir (DTG) and elvitegravir/cobicistat (EVG/COBI), have joined recently the pharmacotherapy arsenal against HIV.
Balboa Barreiro, Vanesa, Castro-Iglesias, Ángeles, Cid-Silva, Purificación, Fernández-Bargiela, Noelia, Llibre, Josep M., Margusino-Framiñán, Luis, Martín-Herranz, Isabel, Pernas, Berta, Poveda, Eva   +8 more
core   +2 more sources

Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration [PDF]

, 2023
BACKGROUND: Tenofovir alafenamide is gradually replacing tenofovir disoproxil fumarate, both prodrugs of tenofovir, in HIV prevention and treatment. There is thus an interest in describing tenofovir pharmacokinetics (PK) and its variability in people ...
Alves Saldanha, Susana, André, Pascal, Buclin, Thierry, Cavassini, Matthias, Courlet, Perrine, Decosterd, Laurent A, Desfontaine, Vincent, Guidi, Monia, Kusejko, Katharina, Swiss HIV Cohort Study, Thoueille, Paul   +10 more
core   +1 more source

2SPD-005 Economical analysis of tenofovir alafenamide versus tenofovir-disoproxil fumarate [PDF]

Section 2: Selection, Procurement and Distribution, 2019
Background Due to the recent commercialisation of the presentations of Tenofovir Alafenamide (TAF) for HIV, there is a need to analyse the costs involved in its introduction into the public health system and its potential impact. Purpose The objective of the study is to assess the cost of using TAF instead of tenofovir-disoproxil fumarate (TDF) in a
M Camean-Castillo, E Rios-Sanchez, MD Gil-Sierra, MP Briceño-Casado, FJ Salmeron-Navas, S Fenix-Caballero, J Diaz-Navarro, C Martinez-Diaz, EJ Alegre-Del Rey, JM Borrero-Rubio   +9 more
openaire   +1 more source

Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide [PDF]

AIDS, 2018
The aim of the study was to compare the intraindividual plasma and intracellular peripheral blood mononuclear cell (PBMC) pharmacokinetics of tenofovir (TFV) and its intracellular metabolite, TFV-diphosphate (TFV-DP) in patients switched from a fixed-dose combination (FDC) tablet of TFV disoproxil fumarate (TDF)/emtricitabine (FTC)/elvitegravir (EVG ...
Anthony T, Podany, Sara H, Bares, Joshua, Havens, Shetty Ravi, Dyavar, Jennifer, O'Neill, Sarah, Lee, Courtney V, Fletcher, Susan, Swindells, Kimberly K, Scarsi   +8 more
openaire   +2 more sources

P99 Renal and bone safety of tenofovir alafenamide vs tenofovir disoproxil fumarate [PDF]

Sexually Transmitted Infections, 2015
Background Off-target renal and bone side effects may occur with tenofovir disoproxil fumarate (TDF) use. Compared with TDF, tenofovir alafenamide (TAF) results in significantly reduced plasma tenofovir (TFV) and may have less renal and bone toxicity.
Frank Post, Paul Sax, Michael Saag, Michael Yin, Shinichi Oka, Ellen Koenig, Benoit Trottier, Jaime Andrade, Huyen Cao, Marshall Fordyce   +9 more
openaire   +1 more source

A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction

BMC Infectious Diseases, 2018
Background Tenofovir alafenamide (TAF) is associated with less renal and bone toxicity compared with tenofovir disoproxil (TDF). TAF's recent FDA approval has spurred HIV providers to consider switching antiretroviral therapy (ART) regimens containing ...
Sarah S. Lee, Joshua P. Havens, Harlan R. Sayles, Jennifer L. O’Neill, Anthony T. Podany, Susan Swindells, Kimberly K. Scarsi, Sara H. Bares   +7 more
doaj   +1 more source

Impact of Combination Antiretroviral Treatment on Liver Metabolic Health in HIV-Infected Persons

Viruses, 2023
In the last three decades, there has been a considerable improvement in human immunodeficiency virus (HIV) therapy. Acquired immunodeficiency syndrome (AIDS) is no longer a common cause of death for people living with HIV (PLWH) in developed countries ...
Michał Biały, Marcin Czarnecki, Małgorzata Inglot   +2 more
doaj   +1 more source

A Phase 2b randomised, controlled, partially blinded trial of the HIV Nucleoside Reverse Transcriptase Inhibitor BMS-986001 (AI467003): Weeks 24 and 48 Efficacy, Safety, Bone and Metabolic Results [PDF]

, 2016
Background BMS-986001 is a thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) designed to maintain in-vitro antiviral activity while minimising off-target effects.
Avihingsanon, Anchalee, Echevarría, Juan, Gupta, Samir K., Hanna, George J., Joshi, Samit R., Lataillade, Max, Lombaard, John, McComsey, Grace A., Orrell, Catherine, Osiyemi, Olayemi, Ray, Neelanjana, Santoscoy, Mario, Stock, David A.   +12 more
core   +1 more source

Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data [PDF]

, 2022
Background: The nucleos(t)ide analogues (NAs) entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are preferred treatment options for patients with chronic hepatitis B infection (CHB).
Agarwal K, Flaherty JF, Fung S, Gordon SC, Hou J, Kao JH, Kurosaki M, Lampertico P., Lim YS, Seto WK, Yee LJ, Zhao Y   +11 more
core   +1 more source

The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV‐Infected Persons [PDF]

Clinical Pharmacology & Therapeutics, 2020
The secondary lymphoid tissues (LT), lymph nodes (LN) and gut‐associated lymphoid tissue are the primary sites of HIV replication and where the latent pool of virus is maintained. We compared the pharmacokinetics of tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) in LT of 13 HIV‐infected persons receiving a TDF‐containing ...
Courtney V. Fletcher, Anthony T. Podany, Ann Thorkelson, Lee C. Winchester, Timothy Mykris, Jodi Anderson, Siri Jorstad, Jason V. Baker, Timothy W. Schacker   +8 more
openaire   +2 more sources